KALA BIO, Inc. (KALA)
Oxford Ledge is still expanding full research coverage of KALA. A delayed quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
KALA BIO is transitioning from a failed rare-disease biopharmaceutical program to developing an AI platform-as-a-service for biotechnology companies.
Source: 10-K (2025-12-31) · AI-generated analysis. Not investment advice. May contain errors.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-05-15
- 8-K 3.03; Amendments to articles or bylaws; Other material event; Financial statements and exhibits 2026-05-07
- 10-K Annual financial report with audited statements 2026-04-15
- 8-K Entry into material agreement; 3.02; Regulation FD disclosure 2026-03-04
- 8-K Departure/election of directors or officers 2026-02-20
Source: SEC EDGAR.
Annual results
5 years of annual figures for KALA, as filed with the SEC. Figures are as reported and are not restated or adjusted.
| Fiscal year | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| 2025 | $0 | -$27.0M | -$3.31 |
| 2024 | $0 | -$38.5M | -$10.15 |
| 2023 | $0 | -$42.2M | -$17.35 |
| 2022 | $3.9M | -$44.8M | -$29.48 |
| 2021 | $11.2M | -$142.6M | -$108.32 |
Source: SEC EDGAR (XBRL company facts). Full statements and ratios in the terminal.
Insider activity
5 recent insider (SEC Form 4) filings on record for KALA. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open KALA in the Oxford Ledge terminal — delayed quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.